You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Multivariate analyses of costs within the first 12 months following allogeneic HSCT for 208 consecutive patients

From: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

Variable Classes Estimated value Wald 95% Confidence Limits P value
Model 1 included age, sex, number of CMV episodes and survival
Intercept 0 €119,539 €101,265 €141,111 <0.0001
Age (years) < 30 1.08 0.95 1.22 0.263
30 to 50 1.07 0.97 1.17 0.1853
≥ 50 1.00 1 1 0
Sex F 0.92 0.84 1.01 0.0647
  M 1.00 1 1 0
Number of CMV episodes 0 0.80 0.70 0.91 0.0008
1 0.84 0.72 0.98 0.0253
≥2 1.00 1 1 0
Survival status Dead 1.08 0.99 1.18 0.0939
Alive 1.00 1 1 0
Model 2 included age, sex, number of CMV episodes, year of transplant and type of graft. Donor/recipient match was excluded because of strong correlation with the type of graft
Intercept 0 €105,461 €86,051 €129,250 <.0001
Age (years) < 30 1.07 0.97 1.18 0.1486
30 to 50 1.06 0.93 1.20 0.3757
≥ 50 1.00 1.00 1.00 0
Sex Females 0.93 0.85 1.02 0.13
  Males 1.00 1.00 1.00 .
Number of CMV episodes 0 0.78 0.68 0.90 0.0003
1 0.83 0.71 0.97 0.0201
≥2 1.00 1.00 1.00 0
Year of transplant 2008 0.83 0.71 0.97 0.0187
2009 1.01 0.87 1.18 0.8646
2010 1.05 0.91 1.22 0.509
2011 1.07 0.92 1.24 0.3775
2012 0.97 0.83 1.13 0.6772
2013 1.00 1.00 1.00 0
Type of graft HLA-identical sibling 1.14 0.96 1.34 0.1242
Unrelated donor 1.13 0.96 1.32 0.1384
Cord Blood Unit 1.00 1.00 1.00 0
  1. We used two models to test explanatory variables that were strongly correlated (e.g age and conditioning)